Titre : Cellules HepG2

Cellules HepG2 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Cicatrix

Questions fréquentes et termes MeSH associés

Diagnostic 2

#1

Comment identifier les cellules HepG2 en laboratoire ?

Les cellules HepG2 peuvent être identifiées par leur morphologie et leur marqueur spécifique, l'alpha-fœtoprotéine.
Carcinome hépatocellulaire Lignées cellulaires
#2

Quelles techniques sont utilisées pour étudier les HepG2 ?

Les techniques incluent la culture cellulaire, la microscopie et les tests de viabilité cellulaire.
Culture cellulaire Microscopie

Symptômes 2

#1

Les cellules HepG2 présentent-elles des symptômes ?

Les cellules HepG2 ne présentent pas de symptômes, car elles sont des cellules in vitro.
Symptômes Cellules in vitro
#2

Quels marqueurs sont associés aux cellules HepG2 ?

Les cellules HepG2 expriment des marqueurs comme l'alpha-fœtoprotéine et des enzymes hépatiques.
Marqueurs tumoraux Enzymes hépatiques

Prévention 2

#1

Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?

Elles sont utilisées pour étudier les effets préventifs de composés sur les maladies hépatiques.
Prévention des maladies Composés bioactifs
#2

Comment les HepG2 contribuent-elles à la recherche préventive ?

Elles permettent d'analyser les effets de l'alimentation et des toxines sur la santé hépatique.
Recherche préventive Toxines

Traitements 2

#1

Peut-on utiliser HepG2 pour tester des médicaments ?

Oui, les cellules HepG2 sont souvent utilisées pour évaluer la toxicité et l'efficacité des médicaments.
Essais cliniques Toxicité
#2

Comment les HepG2 aident-elles à développer des traitements ?

Elles permettent d'étudier les mécanismes d'action des médicaments sur le foie et d'identifier des cibles thérapeutiques.
Développement de médicaments Mécanismes d'action

Complications 2

#1

Quelles complications peuvent être étudiées avec HepG2 ?

Les complications liées aux maladies hépatiques, comme la cirrhose et le cancer du foie, peuvent être modélisées.
Cirrhose Cancer du foie
#2

Les HepG2 aident-elles à comprendre les complications du foie ?

Oui, elles sont essentielles pour étudier les mécanismes des complications hépatiques.
Mécanismes pathologiques Complications hépatiques

Facteurs de risque 2

#1

Quels facteurs de risque sont étudiés avec HepG2 ?

Les facteurs de risque comme l'alcool, les médicaments et les toxines sont souvent analysés.
Facteurs de risque Toxines
#2

Comment HepG2 aide à identifier des facteurs de risque ?

Elles permettent d'évaluer l'impact de divers agents sur la santé des cellules hépatiques.
Évaluation des risques Agents toxiques
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Cellules HepG2 : Questions médicales les plus fréquentes", "headline": "Cellules HepG2 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Cellules HepG2 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-11", "dateModified": "2025-02-05", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Cellules HepG2" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Hépatocytes", "url": "https://questionsmedicales.fr/mesh/D022781", "about": { "@type": "MedicalCondition", "name": "Hépatocytes", "code": { "@type": "MedicalCode", "code": "D022781", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "A11.436.348" } } }, "about": { "@type": "MedicalCondition", "name": "Cellules HepG2", "alternateName": "Hep G2 Cells", "code": { "@type": "MedicalCode", "code": "D056945", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Wilson de Melo Cruvinel", "url": "https://questionsmedicales.fr/author/Wilson%20de%20Melo%20Cruvinel", "affiliation": { "@type": "Organization", "name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil. melocruvinel@gmail.com." } }, { "@type": "Person", "name": "Paulo Luiz Carvalho Francescantonio", "url": "https://questionsmedicales.fr/author/Paulo%20Luiz%20Carvalho%20Francescantonio", "affiliation": { "@type": "Organization", "name": "School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil." } }, { "@type": "Person", "name": "Alessandra Dellavance", "url": "https://questionsmedicales.fr/author/Alessandra%20Dellavance", "affiliation": { "@type": "Organization", "name": "Research and Development Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil." } }, { "@type": "Person", "name": "Luis Eduardo Coelho Andrade", "url": "https://questionsmedicales.fr/author/Luis%20Eduardo%20Coelho%20Andrade", "affiliation": { "@type": "Organization", "name": "Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. luis.andrade@unifesp.br." } }, { "@type": "Person", "name": "Antônio Carlos Ximenes", "url": "https://questionsmedicales.fr/author/Ant%C3%B4nio%20Carlos%20Ximenes", "affiliation": { "@type": "Organization", "name": "Hospital Geral de Goiânia Alberto Rassi, Goiânia, GO, Brazil." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Use of an autologous pericardial patch to repair a post-traumatic caudal vena cava cicatrix in a dog.", "datePublished": "2024-07-15", "url": "https://questionsmedicales.fr/article/39007589", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/vsu.14136" } }, { "@type": "ScholarlyArticle", "name": "Surgical treatment of cesarean scar pregnancy based on the three-category system: a retrospective analysis.", "datePublished": "2024-10-21", "url": "https://questionsmedicales.fr/article/39433995", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12884-024-06887-0" } }, { "@type": "ScholarlyArticle", "name": "Reply to the letter to the Editor \"Treatment of ectopic pregnancy implanted on cesarean scar: other therapeutic approaches\".", "datePublished": "2024-08-13", "url": "https://questionsmedicales.fr/article/39470263", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.18597/rcog.4260" } }, { "@type": "ScholarlyArticle", "name": "Safety in Rhinoplasty: Avoidance and Management of Complications.", "datePublished": "2024-08-10", "url": "https://questionsmedicales.fr/article/39341679", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.fsc.2024.06.008" } }, { "@type": "ScholarlyArticle", "name": "Management of Thick Skin in Rhinoplasty.", "datePublished": "2024-07-29", "url": "https://questionsmedicales.fr/article/39341669", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.fsc.2024.06.004" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Cellules", "item": "https://questionsmedicales.fr/mesh/D002477" }, { "@type": "ListItem", "position": 3, "name": "Cellules épithéliales", "item": "https://questionsmedicales.fr/mesh/D004847" }, { "@type": "ListItem", "position": 4, "name": "Hépatocytes", "item": "https://questionsmedicales.fr/mesh/D022781" }, { "@type": "ListItem", "position": 5, "name": "Cellules HepG2", "item": "https://questionsmedicales.fr/mesh/D056945" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Cellules HepG2 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Cellules HepG2", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-05", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Cellules HepG2", "description": "Comment identifier les cellules HepG2 en laboratoire ?\nQuelles techniques sont utilisées pour étudier les HepG2 ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Cicatrix#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Cellules HepG2", "description": "Les cellules HepG2 présentent-elles des symptômes ?\nQuels marqueurs sont associés aux cellules HepG2 ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Cicatrix#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Cellules HepG2", "description": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?\nComment les HepG2 contribuent-elles à la recherche préventive ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Cicatrix#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Cellules HepG2", "description": "Peut-on utiliser HepG2 pour tester des médicaments ?\nComment les HepG2 aident-elles à développer des traitements ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Cicatrix#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Cellules HepG2", "description": "Quelles complications peuvent être étudiées avec HepG2 ?\nLes HepG2 aident-elles à comprendre les complications du foie ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Cicatrix#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Cellules HepG2", "description": "Quels facteurs de risque sont étudiés avec HepG2 ?\nComment HepG2 aide à identifier des facteurs de risque ?", "url": "https://questionsmedicales.fr/mesh/D056945?mesh_terms=Cicatrix#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment identifier les cellules HepG2 en laboratoire ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules HepG2 peuvent être identifiées par leur morphologie et leur marqueur spécifique, l'alpha-fœtoprotéine." } }, { "@type": "Question", "name": "Quelles techniques sont utilisées pour étudier les HepG2 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les techniques incluent la culture cellulaire, la microscopie et les tests de viabilité cellulaire." } }, { "@type": "Question", "name": "Les cellules HepG2 présentent-elles des symptômes ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules HepG2 ne présentent pas de symptômes, car elles sont des cellules in vitro." } }, { "@type": "Question", "name": "Quels marqueurs sont associés aux cellules HepG2 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les cellules HepG2 expriment des marqueurs comme l'alpha-fœtoprotéine et des enzymes hépatiques." } }, { "@type": "Question", "name": "Les cellules HepG2 peuvent-elles aider à prévenir des maladies ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont utilisées pour étudier les effets préventifs de composés sur les maladies hépatiques." } }, { "@type": "Question", "name": "Comment les HepG2 contribuent-elles à la recherche préventive ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'analyser les effets de l'alimentation et des toxines sur la santé hépatique." } }, { "@type": "Question", "name": "Peut-on utiliser HepG2 pour tester des médicaments ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les cellules HepG2 sont souvent utilisées pour évaluer la toxicité et l'efficacité des médicaments." } }, { "@type": "Question", "name": "Comment les HepG2 aident-elles à développer des traitements ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'étudier les mécanismes d'action des médicaments sur le foie et d'identifier des cibles thérapeutiques." } }, { "@type": "Question", "name": "Quelles complications peuvent être étudiées avec HepG2 ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les complications liées aux maladies hépatiques, comme la cirrhose et le cancer du foie, peuvent être modélisées." } }, { "@type": "Question", "name": "Les HepG2 aident-elles à comprendre les complications du foie ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont essentielles pour étudier les mécanismes des complications hépatiques." } }, { "@type": "Question", "name": "Quels facteurs de risque sont étudiés avec HepG2 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs de risque comme l'alcool, les médicaments et les toxines sont souvent analysés." } }, { "@type": "Question", "name": "Comment HepG2 aide à identifier des facteurs de risque ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Elles permettent d'évaluer l'impact de divers agents sur la santé des cellules hépatiques." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 05/02/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Wilson de Melo Cruvinel

5 publications dans cette catégorie

Affiliations :
  • School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil. melocruvinel@gmail.com.

Paulo Luiz Carvalho Francescantonio

5 publications dans cette catégorie

Affiliations :
  • School of Medical and Life Sciences, Escola de Ciências Médicas e da Vida, Pontifícia Universidade Católica de Goiás (PUC GOIÁS), Avenida Universitária 1.440, Setor Universitário, Goiânia, GO, 74605-010, Brazil.

Alessandra Dellavance

4 publications dans cette catégorie

Affiliations :
  • Research and Development Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil.

Luis Eduardo Coelho Andrade

4 publications dans cette catégorie

Affiliations :
  • Rheumatology Division, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil. luis.andrade@unifesp.br.
  • Immunology Division, Fleury Medicine and Health Laboratories, São Paulo, Brazil. luis.andrade@unifesp.br.

Antônio Carlos Ximenes

3 publications dans cette catégorie

Affiliations :
  • Hospital Geral de Goiânia Alberto Rassi, Goiânia, GO, Brazil.
Publications dans "Cellules HepG2" :

Cristóvão Luis Pitangueira Mangueira

3 publications dans cette catégorie

Affiliations :
  • Departamento de Patologia Clínica e Anatomia Patológica, Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :

Eloísa Bonfá

3 publications dans cette catégorie

Affiliations :
  • Faculdade de Medicina, Hospital das Clinicas HCFMUSP, Universidade de Sao Paulo, São Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :

Fabiano de Almeida Brito

3 publications dans cette catégorie

Affiliations :
  • Department of Clinical Pathology, School of Medicine, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, MG, Brazil.
  • Hermes Pardini Group, Vespasiano, MG, Brazil.
Publications dans "Cellules HepG2" :

Sandra Gofinet Pasoto

3 publications dans cette catégorie

Affiliations :
  • Serviço de Reumatologia e Laboratório de Autoimunidade da Divisão de Laboratório Central do Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.
Publications dans "Cellules HepG2" :

Carlos Alberto von Mühlen

3 publications dans cette catégorie

Affiliations :
  • Sociedade Brasileira de Autoimunidade, Porto Alegre, RS, Brazil.

Tao Chen

2 publications dans cette catégorie

Affiliations :
  • College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :

Xiaoju Wang

2 publications dans cette catégorie

Affiliations :
  • College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :

Lijun Zhou

2 publications dans cette catégorie

Affiliations :
  • College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :

Shiling Feng

2 publications dans cette catégorie

Affiliations :
  • College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :

Ming Yuan

2 publications dans cette catégorie

Affiliations :
  • College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :

Chunbang Ding

2 publications dans cette catégorie

Affiliations :
  • College of Life Science, Sichuan Agricultural University, Ya'an 625014, China.
Publications dans "Cellules HepG2" :

Wei Li

2 publications dans cette catégorie

Affiliations :
  • State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: liv880213@foxmail.com.
Publications dans "Cellules HepG2" :

Xi Xie

2 publications dans cette catégorie

Affiliations :
  • Hainan Provincial Key Laboratory for Tropical Hydrobiology and Biotechnology, School of Marine Science, Hainan University, Haikou 570228, China. Electronic address: xiexi@hainu.edu.cn.
Publications dans "Cellules HepG2" :

Tiantian Wu

2 publications dans cette catégorie

Affiliations :
  • State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: 1532892231@qq.com.
Publications dans "Cellules HepG2" :

Lijie Luo

2 publications dans cette catégorie

Affiliations :
  • State Key Laboratory of Marine Resource Utilization in South China Sea, School of Materials Science and Engineering, Hainan University, Haikou 570228, China. Electronic address: luolijie4567@163.com.
Publications dans "Cellules HepG2" :

Sources (934 au total)

Use of an autologous pericardial patch to repair a post-traumatic caudal vena cava cicatrix in a dog.

To report the use of a pericardial patch graft to repair a post-traumatic caudal vena cava cicatrix in a dog.... Case report.... A 1 year-old Rottweiler presenting with ascites following presumed blunt thoracic trauma.... Kinking of the caudal vena cava and resultant Budd-Chiari-like syndrome was diagnosed on echocardiography and computed tomographic angiography (CTA). Surgical exploration via right sixth intercostal t... The dog recovered from surgery and was discharged after 3 days. Follow-up at 6 weeks showed resolution of ascites and all clinical signs. Owner telephone follow-up at 24 months post-surgery confirmed ... A pericardial patch graft technique can be used successfully to reconstruct the thoracic caudal vena cava, in cases of traumatic kinking where dissection of the fibrotic band alone fails to reduce cau...

Surgical treatment of cesarean scar pregnancy based on the three-category system: a retrospective analysis.

Cesarean scar pregnancy (CSP), a distinct form of ectopic pregnancy, presents challenges in effective management. It is categorized into three subtypes according to the location of placental implantat... In this retrospective analysis, we investigated the cases of 130 patients diagnosed with CSP who underwent diverse treatment approaches, namely ultrasound-guided dilation and curettage (D&C), hysteros... From January 2017 to December 2021, 35 patients underwent D&C, 85 underwent HCoLC, and 10 received UAE as a pretreatment. In the D&C group, the success rates for Type I and Type II CSP were 64.29% (18... The classification of CSP and the measurement of gestational sac are of crucial importance in determining the most appropriate surgical intervention strategy. For patients diagnosed with Type I CSP, D...

Fast absorbing gut sutures in dermatologic surgery: a systematic review and meta-analysis.

Fast gut cutaneous sutures have become more prominent due to their low tissue reactivity, rapid absorption, and elimination of suture removal visits. It is not known how fast gut sutures compare to ot... A comprehensive literature review was conducted to identify randomized controlled trials comparing fast gut sutures to alternative closure methods during dermatologic surgery. Data collected included ... Six studies were included in final analysis and reported on 208 patients. Fast gut sutures were associated with lower physician opinions of final scar when compared to polypropylene sutures (SMD 0.438... If no contraindications to polypropylene sutures exist, they may provide superior cosmetic outcomes compared to fast gut sutures. Further research is required to better quantify cosmetic outcomes and ...

Risk factors for acne scarring in Ecuador.

Acne is a common disease that is associated with scarring and substantial psychosocial burden. The Global Burden of Skin Disease reported that the burden from acne as measured by disability-adjusted l... This was an observational prospective study. Participants were recruited to complete a survey that was developed based on the potential risk factors for acne scarring and had facial photographs taken.... The study included 404 participants. Results from univariate analyses indicated that being male (OR = 2.76 95%CI [1.72; 4.43]), having severe or very severe acne scarring (OR = 4.28 95%CI [1.24; 14.79... By identifying acne scarring risk factors and applying the tool in everyday dermatology visits, we can reduce the physical and psychological burden that acne scarring causes in the adolescent and adul...

Comparison of keratoplasty outcomes at the scar versus edema stages of keratoconus.

To assess the outcomes of deep anterior lamellar keratoplasty or penetrating keratoplasty at the scar and the edema stages.... Forty-five patients (45 eyes) with keratoconus scar stage (scar group, n=26; penetrating keratoplasty a subgroup, n=7; deep anterior lamellar keratoplasty b subgroup, n=19) and keratoconus edema stage... The best-corrected visual acuity and average corneal endothelial cell loss rate were not significantly different between the scar and edema groups (p>0.05). At 6 and 12 months after surgery, the astig... In terms of the outcomes and prognosis for vision after keratoplasty with edema stage and scar stage, deep anterior lamellar keratoplasty may be as effective as penetrating keratoplasty....

A transvaginal ultrasound-based diagnostic calculator for uterus post-cesarean scar defect.

A cesarean scar defect (CSD) is incomplete healing of the myometrium at the site of a prior cesarean section (CS), complicating more than half of all cesarean sections. While transvaginal ultrasound (... A single-center cross-sectional study was conducted on 100 premenopausal and non-pregnant women with a history of CS complaining of AUB without a known systemic or structural etiology. Each participan... Hysteroscopy identified 74 (74%) participants with CSD. The variables age, the number of CSs, defect length, and defect width significantly contributed to the logistic regression model to diagnose CSD... Among non-pregnant women suspected of CSD due to AUB, looking at age, the number of previous CSs, and TVU-based defect width and length can efficiently rule CSD out....